php-banner-video.jpg

UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS.

Emerging Research Emerging Research

The Australia story: Current status and future challenges for the clinical applications of psychedelics

The Australian Therapeutic Goods Administration (TGA) approved the use of psilocybin for treatment-resistant depression and MDMA for PTSD to take effect from 1 July 2023 ... This paper reviews the background for this decision, its implications for approvals in other jurisdictions, as well as for the development pathways for other psychedelic drugs.

Read More
Emerging Research Emerging Research

MindMed announces first patient dosed in phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

Voyage is the first of two Phase 3 studies in GAD evaluating the efficacy and safety of MM120 ODT versus placebo and is expected to enroll approximately 200 participants in the United States. The Panorama study, the second Phase 3 trial, will be conducted in the U.S. and Europe and is on track to initiate in the first half of 2025."

Read More
Emerging Research Emerging Research

Comparative antidepressant effects and safety of intravenous racemic ketamine, psilocybin and theta burst stimulation for major depressive disorder: A systematic review and network meta-analyses of randomized controlled trials

The individual efficacy and safety of intravenous racemic (IV) ketamine, psilocybin, and theta burst stimulation (TBS) for major depressive disorder have been demonstrated through meta-analyses of randomized controlled trials (RCTs), but the comparative usefulness of these novel treatments has not yet been fully examined.

Read More
Emerging Research Emerging Research

Psilocybin therapy for clinicians with symptoms of depression from frontline care during the COVID-19 pandemic: A randomized clinical trial

This randomized clinical trial found that psilocybin therapy resulted in a significant, sustained reduction in symptoms of depression experienced by clinicians after frontline work during the COVID-19 pandemic. The findings establish psilocybin therapy as a new paradigm of treatment for this postpandemic condition.

Read More
Emerging Research Emerging Research

Treatment expectancies and psilocybin vs escitalopram for depression

Our findings have several important implications. First, the large between-group effect size that has been reported for psilocybin in depression may be specific to individuals with low or relatively low expectations of other treatment options.  Second, given the magnitude of the apparent expectancy effect observed within escitalopram recipients, in clinical trials in depression and perhaps in psychiatry more broadly, it may be appropriate to routinely measure treatment expectancies at baseline.

Read More
Emerging Research Emerging Research

RFK could be ‘dangerous’ to psychedelics reform as top federal health official by making issue seem ‘kooky,’ Michael Pollan says

“Psychedelics should be approved because the science is good, not because they have a fan in the White House,” he said, adding that while some in the psychedelics community are “fervently hoping” that Kennedy and other pro-reform Trump picks will “force the hand” of the Food and Drug Administration (FDA) to approve psychedelics as medicine, “politically, I don’t think that’s a good way to go, long-term.”

Read More